These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 34799653)

  • 1. Impact of the molar activity and PSMA expression level on [
    Piron S; Verhoeven J; De Coster E; Descamps B; Kersemans K; Pieters L; Vral A; Vanhove C; De Vos F
    Sci Rep; 2021 Nov; 11(1):22623. PubMed ID: 34799653
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In Vitro and In Vivo Characterization of an
    Lütje S; Franssen GM; Herrmann K; Boerman OC; Rijpkema M; Gotthardt M; Heskamp S
    J Nucl Med; 2019 Jul; 60(7):1017-1022. PubMed ID: 30655329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical Evaluation and Pilot Clinical Study of Al
    Liu T; Liu C; Xu X; Liu F; Guo X; Li N; Wang X; Yang J; Yang X; Zhu H; Yang Z
    J Nucl Med; 2019 Sep; 60(9):1284-1292. PubMed ID: 30796170
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical comparative study of [
    Piron S; Verhoeven J; Courtyn J; Kersemans K; Descamps B; Pieters L; Vral A; Vanhove C; De Vos F
    Sci Rep; 2022 Sep; 12(1):15744. PubMed ID: 36130980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative and Qualitative Analyses of Biodistribution and PET Image Quality of a Novel Radiohybrid PSMA,
    Oh SW; Wurzer A; Teoh EJ; Oh S; Langbein T; Krönke M; Herz M; Kropf S; Wester HJ; Weber WA; Eiber M
    J Nucl Med; 2020 May; 61(5):702-709. PubMed ID: 31836686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of
    Potemkin R; Strauch B; Kuwert T; Prante O; Maschauer S
    Mol Pharm; 2020 Mar; 17(3):933-943. PubMed ID: 32011889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radiation Dosimetry and Biodistribution of
    Piron S; De Man K; Van Laeken N; D'Asseler Y; Bacher K; Kersemans K; Ost P; Decaestecker K; Deseyne P; Fonteyne V; Lumen N; Achten E; Brans B; De Vos F
    J Nucl Med; 2019 Dec; 60(12):1736-1742. PubMed ID: 31028165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiosynthesis and biological evaluation of 18F-labeled bispecific heterodimer targeted dual gastrin-releasing peptide receptor and prostate-specific membrane antigen for prostate cancer imaging.
    Ye S; Li H; Hu K; Li L; Zhong J; Yan Q; Wang Q
    Nucl Med Commun; 2022 Mar; 43(3):323-331. PubMed ID: 34919064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enzalutamide Enhances PSMA Expression of PSMA-Low Prostate Cancer.
    Staniszewska M; Fragoso Costa P; Eiber M; Klose JM; Wosniack J; Reis H; Szarvas T; Hadaschik B; Lückerath K; Herrmann K; Fendler WP; Iking J
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis, preclinical evaluation, and first-in-human study of Al
    Wu Y; Zhang X; Zhou H; Xu B; Tian J; Sun S; Zhang J
    Eur J Nucl Med Mol Imaging; 2022 Jul; 49(8):2774-2785. PubMed ID: 35396969
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intra-individual dynamic comparison of
    Piron S; Verhoeven J; Descamps B; Kersemans K; De Man K; Van Laeken N; Pieters L; Vral A; Vanhove C; De Vos F
    Sci Rep; 2020 Dec; 10(1):21068. PubMed ID: 33273603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiolabeling Optimization and Preclinical Evaluation of the New PSMA Imaging Agent [
    Zha Z; Choi SR; Ploessl K; Alexoff D; Zhao R; Zhu L; Kung HF
    Bioconjug Chem; 2021 May; 32(5):1017-1026. PubMed ID: 33872489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer.
    Chen Y; Pullambhatla M; Foss CA; Byun Y; Nimmagadda S; Senthamizhchelvan S; Sgouros G; Mease RC; Pomper MG
    Clin Cancer Res; 2011 Dec; 17(24):7645-53. PubMed ID: 22042970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Automatic radiosynthesis and preclinical evaluation of
    Zhou W; Huang S; Jiang Y; Hu K; Wang L; Han Y; Wu H
    Amino Acids; 2021 Jun; 53(6):929-938. PubMed ID: 34014365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct in vivo comparison of [
    Ioppolo JA; Nezich RA; Richardson KL; Morandeau L; Leedman PJ; Price RI
    Appl Radiat Isot; 2020 Jul; 161():109164. PubMed ID: 32321698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer.
    Hillier SM; Maresca KP; Femia FJ; Marquis JC; Foss CA; Nguyen N; Zimmerman CN; Barrett JA; Eckelman WC; Pomper MG; Joyal JL; Babich JW
    Cancer Res; 2009 Sep; 69(17):6932-40. PubMed ID: 19706750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of
    Soeda F; Watabe T; Naka S; Liu Y; Horitsugi G; Neels OC; Kopka K; Tatsumi M; Shimosegawa E; Giesel FL; Hatazawa J
    J Nucl Med; 2019 Nov; 60(11):1594-1599. PubMed ID: 30902876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiochemistry and In Vivo Imaging of [
    Saini S; Mullen GED; Blower PJ; Lapi SE
    Mol Pharm; 2024 Feb; 21(2):822-830. PubMed ID: 38173242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical evaluation of BAY 1075553, a novel (18)F-labelled inhibitor of prostate-specific membrane antigen for PET imaging of prostate cancer.
    Lesche R; Kettschau G; Gromov AV; Böhnke N; Borkowski S; Mönning U; Hegele-Hartung C; Döhr O; Dinkelborg LM; Graham K
    Eur J Nucl Med Mol Imaging; 2014 Jan; 41(1):89-101. PubMed ID: 23955632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.